A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Status:
Recruiting
Trial end date:
2025-10-04
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of two doses of belzutifan in participants
with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose
in terms of objective response rate (ORR).